First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features In the overall BOT+BAL treated ...
AgenusInc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus’ multifunctional ...
The BOT+BAL combination arm included 36 heavily pretreated patients with advanced cutaneous melanoma. Most had disease that had resisted prior checkpoint therapy, and many had poor-risk features, ...
“These data reinforce our conviction in BOT+BAL as a mechanistically differentiated CTLA-4-based combination designed to extend the benefit of immunotherapy to patients and tumor types not adequately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results